NEUROVANCE, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.neurovance.com
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Phase 1
Completed
- Conditions
- Drug UsersHealthy Volunteers
- Interventions
- Drug: EB-1020 400 mgDrug: EB-1020 800 mgDrug: Placebo
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Neurovance, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02144415
- Locations
- 🇺🇸
Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States
A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
Phase 1
Completed
- Conditions
- Normal, Healthy Volunteers
- Interventions
- Drug: EB-1020 IROther: PlaceboDrug: EB-1020 SR1Drug: EB-1020 SR2Drug: EB-1020 SR3
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Neurovance, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01744808
- Locations
- 🇦🇺
Nucleus Network Ltd., Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath